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Background: Tip110 plays important roles in tumor immunobiology, pre-mRNA splicing, expression regulation of
viral and host genes, and possibly protein turnover. It is clear that our understanding of Tip110 biological function
remains incomplete.
Results: Herein, we employed an immunoaffinity-based enrichment approach combined with protein mass
spectrometry and attempted to identify Tip110-interacting cellular proteins. A total of 13 major proteins were
identified to be complexed with Tip110. Among them was Y-box binding protein 1 (YB-1). The interaction of Tip110
with YB-1 was further dissected and confirmed to be specific and involve the N-terminal of both Tip110 and YB-1
proteins. A HIV-1 LTR promoter-driven reporter gene assay and a CD44 minigene in vivo splicing assay were chosen
to evaluate the functional relevance of the Tip110/YB-1 interaction. We showed that YB-1 potentiates the Tip110/
Tat-mediated transactivation of the HIV-1 LTR promoter while Tip110 promotes the inclusion of the exon 5 in CD44
minigene alternative splicing.
Conclusions: Tip110 and YB-1 interact to form a complex and mutually regulate each other’s biological functions.
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HIV-1 Tat-interacting protein of 110 kDa (Tip110), also
known as squamous cell carcinoma antigen recognized by
T cells 3 (SART3), was initially identified from a human
myeloid cell line KG-1 cDNA library in 1995 [1]. Several
important biological functions have been attributed to this
gene/protein since its identification. A considerably ele-
vated level of Tip110 is detected in a variety of human can-
cers [2-9], it has been proposed as a tumor antigen for
immunotherapy. In addition, Tip110 binds to small nuclear
RNA U6 and regulates eukaryotic pre-mRNA splicing
([10,11] and our unpublished data). It also preferentially
regulates the inclusion of exon 1a and skipping of exon 1b
of the OCT4 gene [12]. Alteration of splicing components
induced by a mutation in early grey, a Tip110 orthrologue
in zebrafish leads to organ-specific defects and embryonic
death [13], suggesting an important role of Tip110 in devel-
opment. Furthermore, Tip110 is directly involved in expres-
sion regulation of viral and host genes including HIV-1,
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reproduction in any medium, provided the orNANOG, and SOX2 [14-17]. Lastly, Tip110 is shown to
interact with ubiquitin-specific peptidases (USP) such as
USP4 and regulate protein degradation [18]. It is clear that
our understanding of Tip110 biological function is still rap-
idly evolving.
To further understand the biological function of Tip110,
we wished to begin by identifying potential cellular proteins
that interacted with Tip110. We took the immunoaffinity-
based enrichment approach, followed by protein mass spec-
trometry. We isolated a total of 13 Tip110-binding proteins.
Among them was Y-box binding protein 1 (YB-1). In this
study, we characterized Tip110/YB-1 interaction and its
impacts on each other’s function.Methods
Cell culture and transfection 293T cells were purchased
from American Tissue Culture Collection (ATCC) and
grown in Dulbecco’s modified Eagle’s medium containing
10% fetal bovine serum. The cell line was maintained in
100 IU/ml penicillin-100 μg/ml streptomycin and incu-
bated at 37°C in 5% CO2. Cells were transfected using the
standard calcium phosphate precipitation method. TheLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Timani et al. BMC Molecular Biology 2013, 14:14 Page 2 of 7
http://www.biomedcentral.com/1471-2199/14/14chloramphenicol acetyltransferase (CAT) reporter gene
assay was performed as described previously [14].
Plasmids Construction of pTip110-His, pTip110-HA,
ΔCT, ΔRRM, ΔNT, ΔNLS, pTip110-GFP, pTat-Myc plas-
mids have been described elsewhere [14,15]. The pCD44
minigene plasmid was generously provided by Dr. Stefan
Stamm of University of Kentucky, Lexington, KY). The
full length YB-1 cDNA (1-324aa) and the deletion mu-
tants pYB-1ΔC (1-128aa) and pYB-1ΔN (129-324aa)
were generated by standard PCR techniques and inserted
into the mammalian expression plasmid pCMV-Myc by
using the pSPORT6-YB-1 plasmid as a template. Primers
were for pYB-1-Myc: 5′-ATC CGA GAT CTA TAG CAG
CGA GGC CGA GAC-3′ and 5′-AAT ACC TCG AGT
TAC TCA GCC CCG CCC TGC TC-3′; for pYB-1ΔC:
5′-ATC CGA GAT CTA TAG CAG CGA GGC CGA
GAC-3′ and 5′-AAT ACC TCG AGT TAA GGA CCT
GTA ACA TTT GCT GC-3′; for pYB-1ΔN: 5′-ATC CGA
GAT CTATGG TGG TGT TCC AGT TCA AGG-3′ and
5′-AAT ACC TCG AGT TAC TCA GCC CCG CCC
TGC TC-3′. Respective Bgl II and Xho I restriction sites
in the primers were italicized.
Mass spectrometry 293T cells were mock or pTip110-
HA transfected. At 72 hr post-transfection, the cells were
lysed with WCEB buffer (50 mM Tris.HCl, pH 8.0, 280
mM NaCl, 0.5% NP-40, 0.2 mM EDTA, 2 mM EGTA,
10% glycerol, 2 mM PMSF and protease inhibitors) and
applied to the anti-HA affinity matrix column (Roche).
The column was washed with 20 bed-volumes, using wash-
ing buffer (20 mM Tris.HCl, pH 7.5, 0.1 M NaCl; 0.1 mM
EDTA) and then incubated at 37°C with elution buffer
containing HA peptide (1 mg/ml) for 15 min. A portion of
the elutes was mixed with 4× SDS-PAGE loading buffer
and then resolved by 10% SDS-PAGE, and the remaining
elutions were analyzed by LC-MS/MS on a waters Q-Tof
Ultima mass spectrometer at the Yale Cancer Center Mass
spectroscopy and W.M. Keck Foundation and Biotechnol-
ogy, followed by an automated Mascot algorithm against
the NCBI database.
Immunoprecipitation and Western blot analysis
293T cells were transfected with plasmids as indicated
and harvested 72 hr post transfection. The cells were
lysed in WCEB lysis buffer. Lysates were cleared of cell
debris by centrifugation. Antibodies (1–2 μg/mg pro-
tein) were added to the lysates and incubated at 4°C
on a rotating device for 2 hr, and protein A agarose
beads (Upstate, Temecula, CA) were added to precipi-
tate the complex. Pelleted beads were washed and
suspended in 4× SDS loading buffer, boiled and used
for SDS-PAGE. The proteins were transferred onto the
HyBond-P membrane (Amersham, UK). The mem-
brane was probed with primary antibodies and the ap-
propriate peroxidase-labeled secondary antibody, then
visualized with an ECL system.CD44 minigene splicing assay 293T cells were plated
on 6-well plates and grown to 60-70% confluence and
then transfected with the pCD44-v5 splicing reporter,
pTip110-HA, pYB-1 or pYB-1 mutant plasmids. At 72 hr
post transfection, total RNA was isolated using Trizol
(Invitrogen, Carlsbad, CA), followed by acid:phenol extrac-
tion to prevent residual DNA from being used as a PCR
template. Total RNA (0.6 μg) was used for reverse tran-
scriptase (RT)-PCR using the Titan one tube RT-PCR sys-
tem (Roche, Indianapolis, IN) and primers 5′-GAG GGA
TCC GCT CCT GCC CC-3′ and 5′-CTC CCG GGC
CAC CTC CAG TGC C-3′ and a program of 35 cycles of
94°C for 60s, 61°C for 60s, and 72°C for 90s. The RT-PCR
products were separated on a 1% agarose gel.
Data analysis where appropriate, values were expressed
as mean ± SD of triplicate experiments. All comparisons
were made based on the control using two-tailed Student’s
t-test. A p value of < 0.05 was considered statistically sig-
nificant (*), p < 0.01 highly significant (**) and p < 0.001
strongly significant (***). All data were representative of
multiple repeated experiments.
Results
Identification of Tip110-interacting proteins
To identify Tip110-interacting protein, 293T cells were
transfected with pTip110-HA plasmid. Cell lysates were
prepared and passed through a HA-affinity column. Fol-
lowing extensive washes, the bound proteins were eluted
and fractionated on the SDS-PAGE. In parallel, cell lysates
from pcDNA3-transfected cells were also included.
Coomassie blue staining revealed several protein bands
whose intensity differed between samples from Tip110-
HA and pcDNA3 (Figure 1A). Those proteins were recov-
ered for mass spectrometric identification. Besides the bait
protein Tip110 itself, there were 13 major proteins identi-
fied (Table 1). Those included cytoskeletal proteins, heat
shock proteins, ribonucleoproteins, skin proteins and two
ungrouped protein importin-2α and Y box binding protein
1 (YB-1). The interactions of Tip110 with all of those pro-
teins were further examined and confirmed by immuno-
precipitation followed by Western blot analysis (data not
shown and see below). In the study, we chose to focus on
YB-1 protein, as YB-1 and Tip110 appear to possess sev-
eral similar functions. First, both Tip110 and YB-1 protein
bind to RNA and are involved in post-transcriptional
regulation such as pre-mRNA splicing [19,20]. Second,
both Tip110 and YB-1 are highly expressed in some can-
cers [21]. Third, both Tip110 and YB-1 interact with HIV-
1 Tat protein and regulate HIV-1 gene expression. Lastly,
both Tip110 and YB-1 are regulated by transcription fac-
tor c-Myc [16,22]. Thus, all these observations imply that
Tip110 forms complex with YB-1 and regulate each other’s
function and suggest potential physiological significance of
this interaction.
Figure 1 Proteomic analysis of Tip110-binding cellular proteins
including YB-1. A. 293T cells were transfected with pTip110-HA.
pcDNA3 was used in the mock transfection. Seventy-two hours post
transfection, the cells were harvested for cell lysates. The lysates
were applied to an anti-HA affinity matrix column, Tip110-binding
proteins were then eluted from the column and analyzed on 10%
SDS-PAGE followed by Coomassie blue staining. B. 293T cells were
transfected with pTip110-HA, pYB-1-Myc or both and harvested 72
hr post transfection for cell lysates. pcDNA3 was added to equalize
the total amount of transfected DNA. Cell lysates were directly used
for Western blotting using anti-HA or anti-Myc antibody (top panels),
or immunoprecipitated using anti-HA, followed by Western blotting
using anti-HA or anti-Myc antibody (bottom panels). C. 293T cells
were transfected with Tip110-HA and immunoprecipitation was
performed using an anti-HA antibody or isotype-matched IgG,
followed by Western blotting using anti-YB-1 or anti-HA antibody.
Table 1 Tip110-interacting proteins identified by IP
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The proteins were organized into groups based on their functions.
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To confirm Tip110 interaction with YB-1, 293T cells
were transfected with pTip110-HA, pYB-1-Myc, or
both. Western blot analysis using anti-HA or anti-Myc
antibody showed that both Tip110 and YB-1 were
expressed in 293T cells (Figure 1B, top panels). Immu-
noprecipitation of cell lyastes using anti-HA antibody,
followed by Western blotting with anti-Myc or anti-HA
antibody showed that YB-1 was detected in the Tip110-
immunoprecipitates only when Tip110-HA and Myc-YB-1
were co-expressed (Figure 1B, bottom panels). Immuno-
precipitation and Western blotting were performed with
the very same antibody to ensure the immnoprecipitation
efficiency of the antibody. Similar experiments were also
performed with 293T cells transfected with pTip110-HA
only. Endogenous YB-1 was also detected in the Tip110-
immunoprecipitates of Tip110-HA expression cells, but
not present with the isotype IgG-immunoprecipitates
(Figure 1C). Those results suggest that Tip110 complexed
with YB-1 in vivo.
To further determine the specificity of the interaction,
we took advantage of a series of Tip110 mutants that con-
tained deletions of the N-terminal HAT-domain (ΔNT),
RRM domain (ΔRRM), NLS domain (ΔNLS), and the C-
terminal domain (ΔCT) (Figure 2A) [14]. 293T cells weretransfected with pTip110-HA or each of the Tip110 mu-
tants. Tip110 and its mutants were expressed at the
expected molecular weights (Figure 2B, top two panels).
Immunoprecipitation with anti-YB-1 antibody, followed by
Western blot analysis using anti-Tip110 antibody showed
detection of Tip110, ΔCT, ΔRRM and ΔNLS, but not ΔNT
in the YB-1 immunoprecipitates (Figure 2B, bottom two
panels). Similarly, we performed binding experiments of
Tip110 to deletion mutants of YB-1 lacking the N-terminal
(aa1-129, YB-1ΔN) or the C-terminal domains (aa130-324,
YB-1ΔC) (Figure 3A) and found that deletion of the N-
terminal domain of YB-1 (YB-1ΔN) prevented its complex
formation with Tip110 (Figure 3B). Taken together, these
results further confirmed the complex formation between
Tip110 and YB-1 (Table 1) and suggest that the N-terminal
domains of both Tip110 and YB-1 are directly involved in
the complex formation.
YB-1 modulated Tip110/Tat-mediated transactivation of
the HIV-1 LTR promoter
Tip110 interacts with the HIV-1 Tat viral protein and
transactivates the HIV-1 LTR promoter [14,23]. Thus, we
chose a LTR promoter-driven reporter gene chlorampheni-
col acetyltransferase (CAT) to determine the effects of
YB-1 expression on this unique Tip110 function. Initial ex-
periments were performed to optimize the input amounts
of LTR-CAT, Tat, Tip110 and YB-1 expression plasmids to
achieve a lower level of basal level LTR promoter activity
Figure 2 Requirement of Tip110 domains for its binding to
YB-1. A. Scheme of Tip110 and its deletion mutants used in this study.
HAT: half-a-tetratricopeptide repeat; NLS: nuclear localization signal;
RRM: RNA recognition motif. B. 293T cells were transfected with
pTip110-HA or each of Tip110 mutants. Cell lysates were directly used
for Western blotting using anti-Tip110 antibody (top and middle
panels), or immunoprecipitated using anti-YB-1 antibody, followed by
Western blotting using anti-Tip110 (bottom panels). *: Expected
proteins. #: Reactive IgG.
Figure 3 Requirement of YB-1 domains for its binding to
Tip110. A. Scheme of YB-1 and its deletion mutants used in this study.
A/P: Alanine/Proline rich; CSD: cold chock domain; B/A: basic/acidic
repeats. B. 293T cells were transfected with pTip110-HA and pYB-1-Myc,
or one of YB-1 mutants. Cell lysates were directly used for Western
blotting using anti-Myc (top panel) or anti-Tip110 antibody (middle
panel), or immunoprecipitated using anti-HA antibody, followed by
Western blotting using anti-Myc (bottom panel). The long exposure of
the area between the dotted lines was shown at the very bottom panel
for the band marked by an arrowhead. #: Reactive IgG.
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LTR promoter (data not shown). We then transfected 293T
cells with LTR-CAT, Tat, Tip110 and/or increasing amounts
of YB-1 expression plasmids. pcDNA3 was used to equalize
the total amount of DNA transfected, while pC3-GFP
was included in the transfections to normalize the transfec-
tion variations. As expected [14,23], Tip110 or YB-1 expres-
sion increased Tat-mediated transactivation of the LTR
promoter activity (Figure 4). In the presence of Tip110, in-
creased YB-1 expression led to further increase in the Tat-
mediated LTR promoter activity. To further determine the
relationship between the complex formation of Tip110 with
YB-1 and YB-1 effects on Tip110/Tat-mediated transactiva-
tion of the LTR promoter, we performed similar experi-
ments with both YB-1ΔN and YB-1ΔC mutants. YB-1ΔC
mutant expression led to little CAT activity, while YB-1ΔN
mutant showed similar CAT activity as the full-length YB-1.These results suggest that YB-1 expression enhanced
Tip110/Tat-mediated transactivation of the LTR promoter
and suggest that the complex formation of Tip110 and YB-
1 is important for this function. The drastic reduction of
the CAT activity in cells expressing YB-1ΔC to a back-
ground level suggests that YB-1ΔC may function in a dom-
inant negative fashion.Tip110 promoted YB-1-mediated alternative splicing of
CD44 minigene
One of the well-characterized functions of YB-1 is regula-
tion of the alternative splicing of the CD44 gene through
interaction with the A/C-rich exon enhancer element [24].
Figure 4 Effects of YB-1 expression on Tip110/Tat-mediated
transactivation of the HIV-1 LTR promoter. 293T cells were
transfected with 100 ng of pLTR-CAT and various combinations of
pTat-Myc, pTip110-HA, pYB-1-Myc, or each of YB-1 mutants. Input
amounts of plasmids were shown at the top, all were in micrograms
(μg) with the except of pTat-Myc in nanograms (ng). pTat-Myc
plasmid Cells were harvested 72 hr post transfection for the CAT
reporter gene activity assay. pcDNA3 plasmid was added to equalize
the total amount of DNA transfected, while pC3-GFP plasmid was
used to ensure the transfection efficiency among transfections. The
data were mean ± SD and representative of at least three
independent experiments.
Figure 5 Effects of Tip110 expression on YB-1-mediated
alternative splicing of the CD44 minigene. A. Schematic of the
CD44 minigene containing the variable exon 5 (V5). The locations of
the primer set used for RT-PCR were marked by arrows, the dotted
lines indicated two alternative splicing possibilities: one with V5
(top, +V5), the other without V5 (bottom, -V5). B. 293T cells were
transfected with the CD44 minigene plasmid, pYB-1-Myc, pTip110-HA,
or both. Input amounts of plasmids were shown at the top, all were in
micrograms (μg). Total RNA was isolated and used for RT-PCR. The ratio
of V5 inclusion (+V5/–V5) was determined by densitometric scanning
and the ImageJ software and was normalized to that transfected with
the CD44 minigene only. Expression of YB-1 and Tip110 was
determined by Western blotting. β-actin was the loading control.
C. 293T cells were transfected with the CD44 minigene, pYB-1-Myc,
pTip110-HA, or each of the Tip110 mutants. The V5 inclusion and
quantitation were performed as stated above.
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YB-1-mediated CD44 alternative splicing. We took ad-
vantage of a CD44 minigene (Figure 5A) and performed
in vivo RT-PCR-based splicing assay. Initial experiments
were performed to optimize the input amount of CD44
minigene, YB-1 and Tip110 expression plasmids to en-
sure the RT-PCR-based detection of the alternative
splicing (data not shown). As expected [24], YB-1 ex-
pression led to increased inclusion of the variable exon
5 (V5) of the CD44 minigene (Figure 5B, top panels).
Tip110 expression alone appeared to have the similar
enhancement effects. In the presence of YB-1, Tip110
increased inclusion of the V5 exon of CD44 minigene in
a dose-dependent manner. Tip110 and YB-1 expression
were determined by Western blotting to ensure that
Tip110 expression did not alter YB-1 stability (Figure 5B,
bottom panels). We next determined the requirement of
Tip110 binding to YB-1 for this function. Similar in vivo
splicing assay was performed with Tip110ΔNT and
Tip110ΔCT mutants. Compared to the full-length Tip110,
Tip110ΔNT and Tip110ΔCT expression alone showed lit-
tle changes in alternative splicing of the CD44 minigene
(Figure 3C). Interestingly, in the presence of YB-1,
Tip110ΔNT also showed little effects, while Tip110ΔCT
had considerable increase in V5 inclusion of the CD44
minigene. These results suggest that Tip110 binding with
YB-1 plays some roles in YB-1 function.Discussion
In this study, we took the immunoaffinity approach to en-
rich the Tip110-binding proteins and identified those pro-
teins by mass spectrometry. This was followed by further
characterization of Tip110 interaction with YB-1, YB-1 ef-
fects on Tip110-mediated transactivation of the HIV-1
LTR promoter and Tip110 effects on YB-1-mediated alter-
native splicing of CD44 gene. The results showed that
Tip110 bound to YB-1 in a specific manner and the inter-
action mutually regulated each other’s function.
There were a total of 13 major cellular Tip110-binding
proteins, which were grouped according to their func-
tion (Table 1). The group included cytoskeletal proteins,
heat shock proteins, ribonucleoproteins, skin proteins
and two ungrouped protein importin-2α and YB-1. Each
of those proteins likely contributes to either known or
unknown biological function of Tip110. For example,
Tip110 binding to cytoskeletal proteins and skin proteins
may be involved in a Tip110-related skin keratinization
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has been linked to this disease [25-27]. It is conceivable
that Tip110 function in RNA metabolism including pre-
mRNA splicing could require its interaction with ribonu-
cleoproteins and heat shock proteins. The interaction of
Tip110 with improtin-2α could also regulate Tip110 nu-
clear translocation in different cells and under various
physiological conditions. The biological significance of all
those interactions clearly warrants further investigation.
We focused on Tip110/YB-1 interaction in this study.
YB-1 is a multi-functional protein and plays important
roles in transcriptional and translational regulation,
DNA repair, drug resistance and stress responses to
extracellular signals (for review, see [28]). YB-1 has re-
cently been shown to regulate pre-mRNA splicing [29].
Co-immunoprecipitation studies with tagged proteins
and immunoprecipitation of endogenous and exogen-
ous YB-1 with overexpressed Tip110 in 293T cells con-
firmed this protein-protein interaction (Figure 1B & C).
Although Tip110 and YB-1 both contain RNA binding
domains and have been shown to bind to RNA, the
binding properties of Tip110 and YB-1 to each other were
independent of RNA, as we showed that RNase A1 treat-
ment in the cell lysates and during the immunoprecipita-
tion did not alter their complex formation (data not
shown). The specificity of the binding was further sup-
ported by the data obtained from mutagenesis analysis
and showed that the N-terminal domains of both Tip110
and YB-1 were involved in the complex formation
(Figures 2 and 3).
To investigate the functional relevance between the
Tip110 and YB-1 interaction, we tested whether this com-
plex formation affects transactivation of the HIV-1 LTR
promoter and alternative splicing activity. Interaction of
the HIV-1 Tat protein with its cognate RNA TAR is a pre-
requisite for Tat transactivation. Tip110 and YB-1 both
interact with HIV-1 Tat viral protein and potentiate Tat
transactivation in LTR-driven reporter gene assays [14,23].
Although YB-1 has only been shown to bind to the TAR
region of the HIV-LTR, the synergistic effects of Tip110
are TAR-dependent, as these effects are attenuated by de-
letion of the TAR sequence from the HIV-1 LTR pro-
moter. Based on these observations, we speculated that
the Tip110/YB-1 complex affected the transactivation of
HIV-1 LTR promoter activity. The LTR-CAT reporter
gene assay showed that a fixed concentration of Tip110
combined with increasing concentrations of YB-1 resulted
in a further increase in CAT activity (Figure 4), indicating
that the Tip110/YB-1 complex modulates HIV-1 gene ex-
pression. The reporter gene assay with YB-1 mutants
showed that expression of the YB-1ΔC mutant abolished
CAT activity, while expression of the YB-1ΔN mutant en-
hanced the activation to a greater extent than the full
length YB-1. One interesting observation we found duringthe course of this study was that expression of the YB-
1ΔC mutant protein has a negative effect on Tip110 pro-
tein expression by Western blot (data not shown), which
may explain the decrease in CAT activity. Furthermore,
binding of Tat to YB-1 has been mapped to amino acids
75–203 in YB-1, while the YB-1ΔC mutant included
amino acids 1–128. Therefore, there is a stretch of 85
amino acids (residues 128–203) that are important for Tat
binding, that are deleted in the YB-1ΔC mutant, which
may lead to the observed inhibition of CAT activity. Add-
itional studies would be required to determine if the YB-
1ΔC mutant could be utilized to impair Tat function and
effect HIV-1 gene expression.
Alternative splicing represents an important nuclear
mechanism in the post-transcriptional regulation of
gene expression. The role of YB-1 protein in the alter-
native splicing of CD44 is well documented in the litera-
ture. YB-1 binds to A/C-rich exon enhancers and
stimulates splicing of the CD44 alternative variable
exon 4 [24]. CD44 is essential to the physiological activ-
ities of normal cells, but they are also associated with
the pathologic activities of cancer cells (for review, see
[30]). Pre-mRNA from the human CD44 gene under-
goes extensive alternative splicing within a cassette of at
least 10 exons [31]. Increasing inclusion of these exons
has been correlated to cancer and metastasis [32,33].
Here, we utilized a CD44 minigene (Figure 5A) to deter-
mine the physiological function of the Tip110/YB-1
interaction. Our results showed that overexpression of
YB-1 and Tip110 together in 293T cells enhanced the in-
clusion of the variable exon 5 from the CD44 minigene
(Figure 5B). Furthermore, the N-terminal domain of
Tip110 (pTip110ΔCT), which is involved in the inter-
action with YB-1, had higher alternative splicing activity
than the C-terminal domain of Tip110 (pTip110ΔNT).
These results demonstrate the physiological significance of
Tip110/YB-1 complex formation on the alternative spli-
cing regulation of CD44.Conclusions
There are a total of 13 cellular proteins that was identi-
fied by immunoaffinity purification followed by mass
spectrometry. Among those is YB-1. Complex formation
between Tip110 and YB-1 was confirmed by immuno-
precipitation and Western blotting. Both N termini of
Tip110 and YB-1 were found to be required for this
complex formation. YB-1 expression enhanced Tip110-
mediated transactivation of HIV-1 LTR promoter, and
Tip110 expression increased YB-1-mediated CD44 pre-
mRNA alternate splicing.Competing interests
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